NCT04239937 is a clinical trial in Septic Shock, sponsored by Slagelse Hospital.

Who is sponsoring NCT04239937?

NCT04239937 is sponsored by Slagelse Hospital.

What condition does NCT04239937 study?

NCT04239937 studies Septic Shock, Sepsis, Insulin Resistance.

Is NCT04239937 still recruiting?

NCT04239937 is currently status unknown. Last updated 14 August 2020.

Last reviewed 2020-08-14 · How we verify

NCT04239937

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Insulin Resistance in Stress-metabolic Medical Patients

Status unknown Last updated 14 August 2020

What this trial tests

trial in Septic Shock in 50 participants. Status unknown.

Timeline

18 February 2020

Primary endpoint
27 August 2020

27 August 2020

Quick facts

Lead sponsor	Slagelse Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	18 February 2020
Primary completion	27 August 2020
Estimated completion	27 August 2020
Sites	1 location across Denmark

Conditions studied

Septic Shock — all drugs for Septic Shock →
Sepsis — all drugs for Sepsis →
Insulin Resistance — all drugs for Insulin Resistance →

Sponsor

Slagelse Hospital

Who can join

18 and older, any sex, with Septic Shock or Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An observational study on the insulin resistance in sepsis and septic shock patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Septic Shock

Currently open trials in the same condition.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07264543 — Early Methylene Blue in the Microhemodynamics of Septic Patients · Phase 2, PHASE3 · recruiting
NCT04855786 — External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients · NA · recruiting

Other Slagelse Hospital trials

Trials by the same sponsor.

NCT05694351 — Family-based Prevention of Diabetes Through Eating Habits and Physical Activity · NA · completed
NCT05871853 — Get the Benefits From the Start. Improving Breastfeeding · recruiting
NCT05915260 — CMR in T2DM: The NSR Cohort · enrolling by invitation
NCT05322928 — Physically Active Through Daily Occupations With Telehealth · NA · completed
NCT05137080 — Dexamethasone and Functional Outcome After TKA · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04239937 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Slagelse Hospital
Last refreshed: 14 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04239937.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing